|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/09/23 Evolutionary Genomics, Inc. 10-K 12/31/22 58:3.3M Edgar Filing LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 675K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 18K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 18K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 15K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 15K
11: R1 Cover HTML 76K
12: R2 Consolidated Balance Sheets HTML 99K
13: R3 Consolidated Balance Sheets (Parenthetical) HTML 40K
14: R4 Consolidated Statements of Operations HTML 95K
15: R5 Condensed and Consolidated Statement of HTML 50K
Stockholders' Deficit
16: R6 Condensed and Consolidated Statements of Cash HTML 72K
Flows
17: R7 Business Activity HTML 22K
18: R8 Summary of Significant Accounting Policies HTML 36K
19: R9 New Accounting Standards HTML 29K
20: R10 Property and Equipment HTML 31K
21: R11 Intangible Assets HTML 36K
22: R12 Income Taxes HTML 44K
23: R13 Notes Payable HTML 32K
24: R14 Stockholders? Equity HTML 32K
25: R15 Stock-Based Compensation HTML 64K
26: R16 Commitments and Contingencies HTML 26K
27: R17 Related Parties and Transactions HTML 21K
28: R18 Concentrations HTML 19K
29: R19 Liquidity and Going Concern HTML 23K
30: R20 Subsequent Event HTML 19K
31: R21 Summary of Significant Accounting Policies HTML 62K
(Policies)
32: R22 Property and Equipment (Tables) HTML 28K
33: R23 Intangible Assets (Tables) HTML 35K
34: R24 Income Taxes (Tables) HTML 37K
35: R25 Stock-Based Compensation (Tables) HTML 58K
36: R26 Summary of Significant Accounting Policies HTML 29K
(Details Narrative)
37: R27 Property and Equipment (Details) HTML 30K
38: R28 Property and Equipment (Details Narrative) HTML 18K
39: R29 Intangible Assets (Details) HTML 27K
40: R30 Intangible Assets (Details 1) HTML 30K
41: R31 Intangible Assets (Details Narrative) HTML 23K
42: R32 Income Taxes (Details) HTML 36K
43: R33 Income Taxes (Details 1) HTML 40K
44: R34 Income Taxes (Details Narrative) HTML 26K
45: R35 Notes Payable (Details Narrative) HTML 59K
46: R36 Stockholders? Equity (Details Narrative) HTML 43K
47: R37 Stock-Based Compensation (Details) HTML 25K
48: R38 Stock-Based Compensation (Details 1) HTML 53K
49: R39 Stock-Based Compensation (Details Narrative) HTML 29K
50: R40 Commitments and Contingencies (Details Narrative) HTML 37K
51: R41 Related Parties and Transactions (Details HTML 21K
Narrative)
52: R42 Liquidity and Going Concern (Details Narrative) HTML 32K
53: R43 Subsequent Event (Details Narrative) HTML 23K
56: XML IDEA XML File -- Filing Summary XML 98K
54: XML XBRL Instance -- fnam_10k_htm XML 548K
55: EXCEL IDEA Workbook of Financial Reports XLSX 72K
7: EX-101.CAL XBRL Calculations -- fnam-20221231_cal XML 102K
8: EX-101.DEF XBRL Definitions -- fnam-20221231_def XML 243K
9: EX-101.LAB XBRL Labels -- fnam-20221231_lab XML 632K
10: EX-101.PRE XBRL Presentations -- fnam-20221231_pre XML 480K
6: EX-101.SCH XBRL Schema -- fnam-20221231 XSD 98K
57: JSON XBRL Instance as JSON Data -- MetaLinks 273± 402K
58: ZIP XBRL Zipped Folder -- 0001553350-23-000160-xbrl Zip 183K
EXHIBIT 31.1
CERTIFICATION
I, Steve Warnecke, certify that:
1. I have reviewed this annual report on Form 10-K of Evolutionary Genomics, Inc.
2. Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting, to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting .
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information ; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
| March 9, 2023 | |
| BY: | /s/ Steve Warnecke |
| Steve Warnecke | |
| Chief Executive Officer | |
| (principal executive officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/9/23 | None on these Dates | ||
| For Period end: | 12/31/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/13/20 Evolutionary Genomics, Inc. 10-Q 9/30/20 57:30M Edgar Filing LLC/FA 3/30/20 Evolutionary Genomics, Inc. 10-K 12/31/19 61:4.4M Edgar Filing LLC/FA 4/01/19 Evolutionary Genomics, Inc. 10-K 12/31/18 61:29M Edgar Filing LLC/FA 3/05/18 Evolutionary Genomics, Inc. 10-K 12/31/17 59:3M Edgar Filing LLC/FA 2/10/17 Evolutionary Genomics, Inc. 10-K 12/31/16 66:3.8M Edgar Filing LLC/FA 2/25/16 Evolutionary Genomics, Inc. 8-K:3,5,9 2/22/16 3:136K Edgar Filing LLC/FA 10/23/15 Evolutionary Genomics, Inc. 8-K:2,3,4,510/19/15 7:265K Edgar Filing LLC/FA 7/02/15 Evolutionary Genomics, Inc. S-4/A 41:10M Edgar Filing LLC/FA 4/02/15 Evolutionary Genomics, Inc. S-4 36:3.3M Edgar Filing LLC/FA 3/05/15 Evolutionary Genomics, Inc. 10-K 12/31/14 35:2.1M Edgar Filing LLC/FA 9/23/10 Evolutionary Genomics, Inc. 10-12G 9/24/10 6:143K Precision Edgar/FA |